» Articles » PMID: 37779877

Reduced FANCE Confers Genomic Instability and Malignant Behavior by Regulating Cell Cycle Progression in Endometrial Cancer

Overview
Journal J Cancer
Specialty Oncology
Date 2023 Oct 2
PMID 37779877
Authors
Affiliations
Soon will be listed here.
Abstract

Fanconi anemia complementation group E (FANCE) is a subunit of fanconi anemia (FA) pathway and plays a key role in repairing DNA interstrand cross-links (ICLs) damage. We investigate detailed functions and mechanisms of FANCE in endometrial cancer (EC). FANCE protein and RNA expression in EC and non-cancerous tissues were detected by Western blotting (WB), immunohistochemistry (IHC), and real-time polymerase chain reaction (RT-PCR) assays. Using lentiviral transfection and siRNA interference techniques, we constructed overexpressing FANCE (OE-FANCE) and FANCE-knockdown (FANCE-KD) EC cells. We then investigated DNA damage repair capacity of FANCE in EC cells including comet assay and γH2AX immunofluorescence assay. assays including CCK8, EDU and colony formation for chemoresistance and proliferation, transwell assay for metastasis were performed. Flow cytometer assay, cell cycle synchronization for cell cycle progression and EC cells RNA sequencing were determined. Finally, mouse models were used to detect tumor growth. We found FANCE RNA and protein expression was significantly decreased in endometrioid adenocarcinoma (EAC) compared with normal and atypical hyperplasia endometrium. FANCE promoted the repair of ICL damage and double-strand break (DSB) in OE-FANCE EC cells. Furthermore, FANCE increased drug resistance in OE-FANCE EC cells by upregulating FA pathway and homologous recombination (HR) associated proteins. FANCE inhibited cell proliferation and metastasis through G2/M cell cycle arrest and vivo. FANCE participated in regulating several pathways. The study demonstrates the reduction of FANCE expression leads to genomic instability, thereby promoting the development of EC by regulating cell cycle.

Citing Articles

Integrated analysis of FANCE expression and its regulatory role in the immune microenvironment of oral squamous cell carcinoma.

Lin B, Chen Y, Li X, Lin Y, Zhou J, Yang H Oncol Lett. 2025; 29(3):160.

PMID: 39911149 PMC: 11795162. DOI: 10.3892/ol.2025.14906.


Identifying therapeutic targets for primary ovarian insufficiency through integrated genomic analyses.

Du H, Zeng P, Liu X, Zhang J, Huang Z J Ovarian Res. 2024; 17(1):193.

PMID: 39358799 PMC: 11446024. DOI: 10.1186/s13048-024-01524-y.

References
1.
Fuertes M, Castilla J, Alonso C, Perez J . Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem. 2003; 10(3):257-66. DOI: 10.2174/0929867033368484. View

2.
Lu C, Xie M, Wendl M, Wang J, McLellan M, Leiserson M . Patterns and functional implications of rare germline variants across 12 cancer types. Nat Commun. 2015; 6:10086. PMC: 4703835. DOI: 10.1038/ncomms10086. View

3.
Chen G, Deng X . Cell Synchronization by Double Thymidine Block. Bio Protoc. 2018; 8(17). PMC: 6156087. DOI: 10.21769/BioProtoc.2994. View

4.
Rodriguez A, DAndrea A . Fanconi anemia pathway. Curr Biol. 2017; 27(18):R986-R988. DOI: 10.1016/j.cub.2017.07.043. View

5.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View